In-111 DTPA-Octreotide Scintigraphy for Disease Detection in Metastatic Thyroid Cancer: Comparison with F-18 FDG Positron Emission Tomography and Extensive Conventional Radiographic Imaging
暂无分享,去创建一个
[1] O. Clark,et al. Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue , 1992, World Journal of Surgery.
[2] H. Biersack,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer , 1996, European Journal of Nuclear Medicine.
[3] M. Tulchinsky,et al. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation , 1995, European Journal of Nuclear Medicine.
[4] M. Spieth,et al. A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] P. Schöffski,et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.
[6] P. Merlet,et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] R E Carson,et al. Noise reduction in oncology FDG PET images by iterative reconstruction: a quantitative assessment. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] N. Sarlis. Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research. , 2001, Current drug targets. Immune, endocrine and metabolic disorders.
[9] A. Bockisch,et al. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. , 2001, Thyroid : official journal of the American Thyroid Association.
[10] E. Lin,et al. Isotope imaging for metastatic thyroid cancer. , 2001, Endocrinology and metabolism clinics of North America.
[11] E. Krenning,et al. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer , 2001, Journal of endocrinological investigation.
[12] I. Mcdougall,et al. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer , 2001, Nuclear medicine communications.
[13] T. Visser,et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives , 2001, European Journal of Nuclear Medicine.
[14] D. Lee,et al. F‐18‐fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I‐131 scan–negative thyroid carcinoma patients with local recurrence in cervical lymph nodes , 2001, Head & neck.
[15] R. Buchert,et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] R. Tiling,et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] B. Thompson,et al. MR imaging of pulmonary and mediastinal malignancies. , 2000, Magnetic resonance imaging clinics of North America.
[18] M Schwaiger,et al. Quantitative assessment of tumor metabolism using FDG-PET imaging. , 2000, Nuclear medicine and biology.
[19] G. Randolph,et al. The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. , 2000, Radiologic clinics of North America.
[20] J. Llamas-Elvira,et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. , 2000, American journal of surgery.
[21] S. Larson,et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[22] S. Larson,et al. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. , 2000, Thyroid : official journal of the American Thyroid Association.
[23] Scott T. Grafton,et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. , 1999, Thyroid : official journal of the American Thyroid Association.
[24] D. Lee,et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] N. Valli,et al. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. , 1999, Thyroid : official journal of the American Thyroid Association.
[26] E. Krenning,et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] M. Starlinger,et al. Comparison of different tracers in the follow up of differentiated thyroid carcinoma. , 1999, Acta medica Austriaca.
[28] A. Bockisch,et al. [Somatostatin receptor status in non-medullary thyroid carcinoma]. , 1999, Nuklearmedizin. Nuclear medicine.
[29] S. Larson,et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.
[30] P. Ladenson,et al. Prospective multicenter study of thyroid carcinoma treatment , 1998 .
[31] P. Ladenson,et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.
[32] A. Devillers,et al. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake , 1998, European Journal of Nuclear Medicine.
[33] H. Jadvar,et al. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. , 1998, Nuclear medicine communications.
[34] O. Schober,et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans , 1998, Langenbeck's Archives of Surgery.
[35] E P Krenning,et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. , 1998, Cancer research.
[36] E P Krenning,et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. , 1998, Nuclear medicine communications.
[37] D. Burstein,et al. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. , 1997, Thyroid : official journal of the American Thyroid Association.
[38] M. Knoll,et al. HLA class II expression in well differentiated thyroid carcinoma: correlation with clinicopathological features. , 1997, Journal of experimental & clinical cancer research : CR.
[39] K. Ain,et al. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. , 1997, The Journal of clinical endocrinology and metabolism.
[40] J. Reynolds,et al. The changing role of radioiodine in the management of differentiated thyroid cancer. , 1997, Seminars in nuclear medicine.
[41] J. Hanke,et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[42] J. Laissue,et al. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. , 1996, Metabolism: clinical and experimental.
[43] E. Baudin,et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. , 1996, The Journal of clinical endocrinology and metabolism.
[44] H. van Toor,et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. , 1996, Digestion.
[45] C. Spencer,et al. Current status and performance goals for serum thyroglobulin assays. , 1996, Clinical chemistry.
[46] B. Caillou,et al. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[47] K. Ain,et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. , 1995, The Journal of clinical endocrinology and metabolism.
[48] S. Jhiang,et al. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.
[49] H. Maxon,et al. Imaging modalities in the follow-up of non-iodine avid thyroid carcinoma. , 1994, American journal of otolaryngology.
[50] T G Turkington,et al. Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[51] G. Mengod,et al. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. , 1994, Cancer research.
[52] K. Ain,et al. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. , 1994, The Journal of clinical endocrinology and metabolism.
[53] H. Minn,et al. Expression of glucose transporters in head‐and‐neck tumors , 1994, International journal of cancer.
[54] S. Hanau,et al. Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro. , 1991, The Journal of clinical endocrinology and metabolism.
[55] A. Moses,et al. Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells. , 1990, Endocrinology.
[56] H. Joensuu,et al. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] L. Degroot,et al. Use of isotope bone scans and skeletal survey X-rays in the follow-up of patients with thyroid carcinoma , 1984, Journal of endocrinological investigation.
[58] S. Yeh,et al. Bone Scans in Bone Metastases from Functioning Thyroid Carcinoma , 1980, Clinical nuclear medicine.